Ironwood Pharmaceuticals (IRWD) to Release Quarterly Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Rating) will post its quarterly earnings results before the market opens on Thursday, May 5th. Analysts expect Ironwood Pharmaceuticals to post earnings of $0.31 per share for the quarter. Ironwood Pharmaceuticals has set its FY 2022 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Rating) last issued its quarterly earnings results on Thursday, February 17th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.31 by ($0.04). Ironwood Pharmaceuticals had a return on equity of 42.43% and a net margin of 127.72%. The business had revenue of $117.13 million during the quarter, compared to analysts’ expectations of $110.18 million. During the same quarter in the previous year, the company posted $0.36 EPS. The company’s quarterly revenue was up .4% on a year-over-year basis. On average, analysts expect Ironwood Pharmaceuticals to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Shares of IRWD stock opened at $11.89 on Thursday. Ironwood Pharmaceuticals has a 52-week low of $10.13 and a 52-week high of $14.27. The company has a debt-to-equity ratio of 0.56, a quick ratio of 4.61 and a current ratio of 4.61. The firm has a market capitalization of $1.89 billion, a PE ratio of 3.68 and a beta of 1.22. The stock has a fifty day simple moving average of $11.94 and a two-hundred day simple moving average of $11.84.

Several research firms have commented on IRWD. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. TheStreet raised shares of Ironwood Pharmaceuticals from a “c” rating to a “b-” rating in a report on Wednesday, January 19th. Finally, Piper Sandler began coverage on shares of Ironwood Pharmaceuticals in a report on Friday, April 22nd. They set an “overweight” rating and a $16.00 price objective for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $14.75.

In related news, insider Ronald Silver sold 3,031 shares of the stock in a transaction dated Thursday, March 24th. The shares were sold at an average price of $12.75, for a total value of $38,645.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.60% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 15.2% in the 4th quarter. BlackRock Inc. now owns 14,368,890 shares of the biotechnology company’s stock valued at $167,541,000 after acquiring an additional 1,897,115 shares during the last quarter. Millennium Management LLC lifted its stake in Ironwood Pharmaceuticals by 2.9% in the fourth quarter. Millennium Management LLC now owns 1,589,816 shares of the biotechnology company’s stock worth $18,537,000 after purchasing an additional 44,334 shares during the last quarter. Invesco Ltd. lifted its stake in Ironwood Pharmaceuticals by 8.7% in the fourth quarter. Invesco Ltd. now owns 762,182 shares of the biotechnology company’s stock worth $8,887,000 after purchasing an additional 60,905 shares during the last quarter. Comerica Bank lifted its stake in Ironwood Pharmaceuticals by 20.7% in the fourth quarter. Comerica Bank now owns 602,957 shares of the biotechnology company’s stock worth $6,717,000 after purchasing an additional 103,370 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in Ironwood Pharmaceuticals by 17.6% in the fourth quarter. Parametric Portfolio Associates LLC now owns 544,769 shares of the biotechnology company’s stock worth $6,352,000 after purchasing an additional 81,614 shares during the last quarter.

About Ironwood Pharmaceuticals (Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

See Also

Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.